NCT01447758 - Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Atopic Dermatitis

Interventions

DRUG

LEO 29102

Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV

DRUG

LEO 29102 Cream Vehicle

Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV

Trial Locations (8)

Charité - Universitätsmedizin Berlin, Berlin

Clinical Trial Center North, Hamburg

Medizinische Hochschule Hannover, Hanover

Universitätshautklinik Essen, Essen

Universitätshautklinik Münster, Münster

Klinik und Poliklinik für Dermatologie und Allergologie der Universität Bonn, Bonn

Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main

SRH Wald-Klinikum Gera gGmbH, Gera